Mitoception: A Novel Strategy to Alleviate Pulmonary Fibrosis

Area of Science:

• Cell Biology
• Mitochondrial Biology
• Pulmonary Medicine

Background:

• Pulmonary fibrosis (PF) is a severe lung disease with limited treatments, characterized by scarring and high mortality.
• Mitochondrial dysfunction is a key driver of fibroblast activation in PF, but therapeutic restoration remains underdeveloped.
• Alveolar type II epithelial cells (A549) and patient-derived fibroblasts are relevant cell types in PF pathogenesis.

Purpose of the Study:

• To investigate if mitochondrial transfer from A549 cells to patient-derived fibroblasts can restore mitochondrial function and bioenergetics in PF.
• To assess the impact of mitochondrial transfer on profibrotic signaling and cellular respiration in diseased fibroblasts.

Main Methods:

• Functional validation of isolated donor mitochondria using Seahorse analysis.
• Confirmation of patient-derived fibroblasts using qRT-PCR.
• In vitro assessment of mitochondrial transfer (mitoception) into diseased fibroblasts.
• Analysis of mitochondrial membrane potential, gene expression, and cellular respiration post-mitoception.

Main Results:

• Mitochondrial transfer led to a dose- and time-dependent increase in mitochondrial membrane potential in diseased fibroblasts.
• Gene expression analysis showed reduced fibrosis markers and increased mitochondrial/antioxidant gene expression after mitoception.
• Seahorse analysis revealed enhanced ATP-linked respiration and improved bioenergetic parameters, though maximal respiration varied.

Conclusions:

• Mitochondrial transfer effectively modulated fibroblast bioenergetics and profibrotic signaling in vitro.
• This study supports mitochondrial transfer as a potential therapeutic strategy for pulmonary fibrosis.
• Restoring mitochondrial function via transfer offers a novel approach to combat PF progression.